BioNewsRound Award finalist!

Neuro-Bio Ltd are delighted to announce that we have been short listed for the BioNewsRound Award. Our CEO, Susan Greenfield will be presenting a short presentation at the ON Helix Welcome Reception on 27th June. You can find out more information on their website, here.

Alzheimer’s Disease: Defusing The Bomb By 2025

Published in In Vivo Beyond Beta-Amyloid  The US FDA has approved six drugs to treat Alzheimer’s symptoms, all of which work by increasing the amount of neurotransmitters in the brain, helping nerve cells in the brain to communicate. These approved therapies are: Razadyne (galantamine), Exelon (rivastigmine), Aricept, Namenda,Namzaric (memantine + donepezil) and Cognex, which is no longer widely sold in the US. None of these drugs prevent or treat the cause of Alzheimer’s, nor do they slow progression of the disease.

BBC Business LIVE

Baroness Susan Greenfield will be on BBC Business Live on Monday 16th May, talking about Alzheimer’s Disease and Neuro-Bio Ltd. If you missed this, you can catch up by clicking, here.  

Best of Luck to Dr Garcia-Rates

Dr Sara Garcia-Rates left Neuro-Bio Ltd in January 2016 on Maternity leave. Neuro-Bio would like to congratulate her and her husband, and wish them the very best of luck to becoming parents. Dr Garcia-Rates will be returning to Neuro-Bio Ltd in July 2016.

Generous Donation

Neuro-Bio would like to thank Ms. Josie Duffy for the further generous donation to our research of £500, all through her valuable fundraising. 

12th ChE- 6PON Meeting, Alicante

Neuro-Bio took part in this years Biological Functions of ChES and related diseases session at the 12th International Meeting of Cholinesterases – 6th-Paraoxonase Conference in Alicante, Spain.FullSizeRenderFullSizeRender3FullSizeRender2